Allergan and Editas Report First Patient Dosing in P-I/II BRILLIANCE Study with AGN-151587 (EDIT-101) to Treat LCA10

 Allergan and Editas Report First Patient Dosing in P-I/II BRILLIANCE Study with AGN-151587 (EDIT-101) to Treat LCA10

Allergan and Editas Report First Patient Dosing in P-I/II BRILLIANCE Study with AGN-151587 (EDIT-101) to Treat LCA10

Shots:

  • The P-I/II study will assess the safety & efficacy of AGN-151587 (subretinal injection) in ~18 patients with Leber congenital amaurosis 10. The patients enrolled are both adult & pediatric patients (aged 3-17yrs.)
  • The first patients dosing in BRILLIANCE study marks a significant milestone toward delivering the CRISPR medicines, treating the devastating LCA10
  • AGN-151587 (EDIT-101) is a CRISPR-based investigational therapy, intended to treat LCA10 and is administered via a subretinal injection to deliver the gene-editing machinery directly to photoreceptor cells

Click here ­to­ read full press release/ article | Ref: Editas | Image: Pharma Advancement

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post